1. Home
  2. PMAX vs PRFX Comparison

PMAX vs PRFX Comparison

Compare PMAX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

N/A

Current Price

$1.24

Market Cap

2.7M

Sector

N/A

ML Signal

N/A

Logo PainReform Ltd.

PRFX

PainReform Ltd.

N/A

Current Price

$0.97

Market Cap

2.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMAX
PRFX
Founded
2019
2007
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.6M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
PMAX
PRFX
Price
$1.24
$0.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.0M
263.5K
Earning Date
05-12-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.58
52 Week High
$5.20
$5.39

Technical Indicators

Market Signals
Indicator
PMAX
PRFX
Relative Strength Index (RSI) 57.61 48.81
Support Level $0.89 $0.91
Resistance Level $1.38 $1.25
Average True Range (ATR) 0.32 0.10
MACD 0.09 0.01
Stochastic Oscillator 26.88 29.73

Price Performance

Historical Comparison
PMAX
PRFX

About PMAX Powell Max Limited

Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

Share on Social Networks: